Evidence map›Paper›PMID 29374999›Full record

ArticleCell cycle (Georgetown, Tex.)2018

Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.

Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, Kentaro Miyake, Masuyo Miyake, Shukuan Li, Qinghong Han, Yuying Tan, Ming Zhao, Yunfeng Li and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Acta biochimica et biophysica Sinica · 2023
    Review
  13. Frontiers in cellular and infection microbiology · 2023
    Review
  14. Pharmaceutics · 2022
    Review
  15. Recombinant AttenuatedCancers · 2022
    Review
  16. IFN-γ enhances the antitumor activity of attenuatedFrontiers in bioengineering and biotechnology · 2022
    Article
  17. Article
  18. Synergistic effects of arsenic trioxide combined withJournal of gastrointestinal oncology · 2021
    Article
  19. Integration ofCancers · 2021
    Review
  20. Perspectives on OncolyticFrontiers in immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 2 countries.

Kentaro Igarashia AntiCancer, Inc. , San Diego , CA, USA.
Kei Kawaguchia AntiCancer, Inc. , San Diego , CA, USA.
Tasuku Kiyunaa AntiCancer, Inc. , San Diego , CA, USA.
Kentaro Miyakea AntiCancer, Inc. , San Diego , CA, USA.
Masuyo Miyakea AntiCancer, Inc. , San Diego , CA, USA.
Shukuan Lia AntiCancer, Inc. , San Diego , CA, USA.
Qinghong Hana AntiCancer, Inc. , San Diego , CA, USA.
Yuying Tana AntiCancer, Inc. , San Diego , CA, USA.
Ming Zhaoa AntiCancer, Inc. , San Diego , CA, USA.
Yunfeng Lid Dept. of Pathology , University of California , Los Angeles , CA , USA.
Scott D Nelsond Dept. of Pathology , University of California , Los Angeles , CA , USA.
Sarah M Dryd Dept. of Pathology , University of California , Los Angeles , CA , USA.
Arun S Singhe Division of Hematology-Oncology , University of California , Los Angeles , CA , USA.
Irmina A Elliottf Division of Surgical Oncology , University of California , Los Angeles , CA , USA.
Tara A Russellf Division of Surgical Oncology , University of California , Los Angeles , CA , USA.ORCID 0000-0002-3912-3601
Mark A Eckardtg Department of Surgery, Yale School of Medicine , New Haven , CT, USA.ORCID 0000-0002-9528-8419
Norio Yamamotoc Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Katsuhiro Hayashic Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Hiroaki Kimurac Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Shinji Miwac Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Hiroyuki Tsuchiyac Department of Orthopaedic Surgery , Kanazawa University , Kanazawa , Japan.
Fritz C Eilberf Division of Surgical Oncology , University of California , Los Angeles , CA , USA.ORCID 0000-0003-3336-9333
Robert M Hoffmana AntiCancer, Inc. , San Diego , CA, USA.
University of California, Los Angeles · USKanazawa University · JPUniversity of California San Diego · USAntiCancer (United States) · USYale University · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Establishment of a patient-like mouse models of soft-tissue sarcoma sub-typesR43CA213649 · NCI · ANTICANCER, INC. · PI HOFFMAN, ROBERT M · 2017 to 2017
$225k
NCI NIH HHS P30 CA016042NCI NIH HHS R43 CA213649
6 · The paper itself

Abstract

In the present study, a patient-derived orthotopic xenograft (PDOX) model of recurrent cisplatinum (CDDP)-resistant metastatic osteosarcoma was treated with Salmonella typhimurium A1-R (S. typhimurium A1-R), which decoys chemoresistant quiescent cancer cells to cycle, and recombinant methioninase (rMETase), which selectively traps cancer cells in late S/G

Indexed as

AnimalsAntineoplastic AgentsCarbon-Sulfur LyasesCisplatinDisease Models, AnimalDrug Resistance, NeoplasmDrug Therapy, CombinationG2 Phase Cell Cycle CheckpointsHumansLung NeoplasmsMiceMice, NudeNeoplasm Recurrence, LocalOsteosarcomaRecombinant ProteinsSalmonella typhimuriumAntineoplastic AgentsCarbon-Sulfur LyasesCisplatinL-methionine gamma-lyaseRecombinant ProteinscisplatinumdecoykilllungmetastasismethioninaseosteosarcomaPDOXresistanceSalmonella typhimurium A1-Rtrap

Identifiers

PMID29374999
PMCPMC5969544
OpenAlexW2797091043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.